Skip to main content
Top
Published in: Critical Care 4/2012

Open Access 01-08-2012 | Research

Plasma suPAR levels are associated with mortality, admission time, and Charlson Comorbidity Index in the acutely admitted medical patient: a prospective observational study

Authors: Thomas Huneck Haupt, Janne Petersen, Gertrude Ellekilde, Henrik Hedegaard Klausen, Christian Wandall Thorball, Jesper Eugen-Olsen, Ove Andersen

Published in: Critical Care | Issue 4/2012

Login to get access

Abstract

Introduction

Soluble urokinase plasminogen activator receptor (suPAR) is the soluble form of the membrane-bound receptor (uPAR) expressed predominantly on various immune cells. Elevated plasma suPAR concentration is associated with increased mortality in various patient groups, and it is speculated that suPAR is a low-grade inflammation marker reflecting on disease severity. The aim of this prospective observational study was to determine if the plasma concentration of suPAR is associated with admission time, re-admission, disease severity/Charlson Comorbidity Index Score, and mortality.

Methods

We included 543 patients with various diseases from a Danish Acute Medical Unit during a two month period. A triage unit ensured that only medical patients were admitted to the Acute Medical Unit. SuPAR was measured on plasma samples drawn upon admission. Patients were followed-up for three months after inclusion by their unique civil registry number and using Danish registries to determine admission times, readmissions, International Classification of Diseases, 10th Edition (ICD-10) diagnoses, and mortality. Statistical analysis was used to determine suPAR's association with these endpoints.

Results

Increased suPAR was significantly associated with 90-day mortality (4.87 ng/ml in survivors versus 7.29 ng/ml in non-survivors, P < 0.0001), higher Charlson Score (P < 0.0001), and longer admission time (P < 0.0001), but not with readmissions. The association with mortality remained when adjusting for age, sex, C-reactive protein (CRP), and Charlson Score. Furthermore, among the various Charlson Score disease groups, suPAR was significantly higher in those with diabetes, cancer, cardiovascular disease, and liver disease compared to those without comorbidities.

Conclusions

SuPAR is a marker of disease severity, admission time, and risk of mortality in a heterogeneous cohort of patients with a variety of diseases. The independent value of suPAR suggests it could be of value in prognostic algorithms.
Appendix
Available only for authorised users
Literature
1.
go back to reference Montuori N, Ragno P: Multiple activities of a multifaceted receptor: roles of cleaved and soluble uPAR. Front Biosci 2009, 14: 2494-2503.CrossRef Montuori N, Ragno P: Multiple activities of a multifaceted receptor: roles of cleaved and soluble uPAR. Front Biosci 2009, 14: 2494-2503.CrossRef
2.
go back to reference Blasi F, Sidenius N: The urokinase receptor: focused cell surface proteolysis, cell adhesion and signaling. FEBS Lett 2010, 584: 1923-1930. 10.1016/j.febslet.2009.12.039PubMedCrossRef Blasi F, Sidenius N: The urokinase receptor: focused cell surface proteolysis, cell adhesion and signaling. FEBS Lett 2010, 584: 1923-1930. 10.1016/j.febslet.2009.12.039PubMedCrossRef
3.
go back to reference Eugen-Olsen J, Gustafson P, Sidenius N, Fischer TK, Parner J, Aaby P, Gomes VF, Lisse I: The serum level of soluble urokinase receptor is elevated in tuberculosis patients and predicts mortality during treatment: a community study from Guinea-Bissau. Int J Tuberc Lung Dis 2002, 6: 686-692.PubMed Eugen-Olsen J, Gustafson P, Sidenius N, Fischer TK, Parner J, Aaby P, Gomes VF, Lisse I: The serum level of soluble urokinase receptor is elevated in tuberculosis patients and predicts mortality during treatment: a community study from Guinea-Bissau. Int J Tuberc Lung Dis 2002, 6: 686-692.PubMed
4.
go back to reference Sidenius N, Sier CF, Ullum H, Pedersen BK, Lepri AC, Blasi F, Eugen-Olsen J: Serum level of soluble urokinase-type plasminogen activator receptor is a strong and independent predictor of survival in human immunodeficiency virus infection. Blood 2000, 96: 4091-4095.PubMed Sidenius N, Sier CF, Ullum H, Pedersen BK, Lepri AC, Blasi F, Eugen-Olsen J: Serum level of soluble urokinase-type plasminogen activator receptor is a strong and independent predictor of survival in human immunodeficiency virus infection. Blood 2000, 96: 4091-4095.PubMed
5.
go back to reference Wittenhagen P, Andersen JB, Hansen A, Lindholm L, Ronne F, Theil J, Tvede M, Eugen-Olsen J: Plasma soluble urokinase plasminogen activator receptor in children with urinary tract infection. Biomark Insights 2011, 6: 79-82.PubMedPubMedCentralCrossRef Wittenhagen P, Andersen JB, Hansen A, Lindholm L, Ronne F, Theil J, Tvede M, Eugen-Olsen J: Plasma soluble urokinase plasminogen activator receptor in children with urinary tract infection. Biomark Insights 2011, 6: 79-82.PubMedPubMedCentralCrossRef
6.
go back to reference Koch A, Voigt S, Kruschinski C, Sanson E, Duckers H, Horn A, Yagmur E, Zimmermann H, Trautwein C, Tacke F: Circulating soluble urokinase plasminogen activator receptor is stably elevated during the first week of treatment in the intensive care unit and predicts mortality in critically ill patients. Crit Care 2011, 15: R63. 10.1186/cc10037PubMedPubMedCentralCrossRef Koch A, Voigt S, Kruschinski C, Sanson E, Duckers H, Horn A, Yagmur E, Zimmermann H, Trautwein C, Tacke F: Circulating soluble urokinase plasminogen activator receptor is stably elevated during the first week of treatment in the intensive care unit and predicts mortality in critically ill patients. Crit Care 2011, 15: R63. 10.1186/cc10037PubMedPubMedCentralCrossRef
8.
go back to reference Huttunen R, Syrjanen J, Vuento R, Hurme M, Huhtala H, Laine J, Pessi T, Aittoniemi J: Plasma level of soluble urokinase-type plasminogen activator receptor as a predictor of disease severity and case fatality in patients with bacteraemia: a prospective cohort study. J Intern Med 2011, 270: 32-40. 10.1111/j.1365-2796.2011.02363.xPubMedCrossRef Huttunen R, Syrjanen J, Vuento R, Hurme M, Huhtala H, Laine J, Pessi T, Aittoniemi J: Plasma level of soluble urokinase-type plasminogen activator receptor as a predictor of disease severity and case fatality in patients with bacteraemia: a prospective cohort study. J Intern Med 2011, 270: 32-40. 10.1111/j.1365-2796.2011.02363.xPubMedCrossRef
9.
go back to reference Rabna P, Andersen A, Wejse C, Oliveira I, Gomes VF, Haaland MB, Aaby P, Eugen-Olsen J: High mortality risk among individuals assumed to be TB-negative can be predicted using a simple test. Trop Med Int Health 2009, 14: 986-994. 10.1111/j.1365-3156.2009.02328.xPubMedCrossRef Rabna P, Andersen A, Wejse C, Oliveira I, Gomes VF, Haaland MB, Aaby P, Eugen-Olsen J: High mortality risk among individuals assumed to be TB-negative can be predicted using a simple test. Trop Med Int Health 2009, 14: 986-994. 10.1111/j.1365-3156.2009.02328.xPubMedCrossRef
10.
go back to reference Christensen S, Johansen MB, Christiansen CF, Jensen R, Lemeshow S: Comparison of Charlson comorbidity index with SAPS and APACHE scores for prediction of mortality following intensive care. Clin Epidemiol 2011, 3: 203-211.PubMedPubMedCentralCrossRef Christensen S, Johansen MB, Christiansen CF, Jensen R, Lemeshow S: Comparison of Charlson comorbidity index with SAPS and APACHE scores for prediction of mortality following intensive care. Clin Epidemiol 2011, 3: 203-211.PubMedPubMedCentralCrossRef
11.
go back to reference Eugen-Olsen J: suPAR - a future risk marker in bacteremia. J Intern Med 2011, 270: 29-31. 10.1111/j.1365-2796.2011.02372.xPubMedCrossRef Eugen-Olsen J: suPAR - a future risk marker in bacteremia. J Intern Med 2011, 270: 29-31. 10.1111/j.1365-2796.2011.02372.xPubMedCrossRef
12.
go back to reference Eugen-Olsen J, Andersen O, Linneberg A, Ladelund S, Hansen TW, Langkilde A, Petersen J, Pielak T, Møller LN, Jeppesen J, Lyngbaek S, Fenger M, Olsen MH, Hildebrandt PR, Borch-Johnsen K, Jørgensen T, Haugaard SB: Circulating soluble urokinase plasminogen activator receptor predicts cancer, cardiovascular disease, diabetes and mortality in the general population. J Intern Med 2010, 268: 296-308. 10.1111/j.1365-2796.2010.02252.xPubMedCrossRef Eugen-Olsen J, Andersen O, Linneberg A, Ladelund S, Hansen TW, Langkilde A, Petersen J, Pielak T, Møller LN, Jeppesen J, Lyngbaek S, Fenger M, Olsen MH, Hildebrandt PR, Borch-Johnsen K, Jørgensen T, Haugaard SB: Circulating soluble urokinase plasminogen activator receptor predicts cancer, cardiovascular disease, diabetes and mortality in the general population. J Intern Med 2010, 268: 296-308. 10.1111/j.1365-2796.2010.02252.xPubMedCrossRef
13.
go back to reference Riisbro R, Christensen IJ, Hogdall C, Brunner N, Hogdall E: Soluble urokinase plasminogen activator receptor measurements: influence of sample handling. Int J Biol Markers 2001, 16: 233-239.PubMed Riisbro R, Christensen IJ, Hogdall C, Brunner N, Hogdall E: Soluble urokinase plasminogen activator receptor measurements: influence of sample handling. Int J Biol Markers 2001, 16: 233-239.PubMed
14.
go back to reference Januel JM, Luthi JC, Quan H, Borst F, Taffe P, Ghali WA, Burnand B: Improved accuracy of co-morbidity coding over time after the introduction of ICD-10 administrative data. BMC Health Serv Res 2011, 11: 194. 10.1186/1472-6963-11-194PubMedPubMedCentralCrossRef Januel JM, Luthi JC, Quan H, Borst F, Taffe P, Ghali WA, Burnand B: Improved accuracy of co-morbidity coding over time after the introduction of ICD-10 administrative data. BMC Health Serv Res 2011, 11: 194. 10.1186/1472-6963-11-194PubMedPubMedCentralCrossRef
15.
go back to reference Ostrowski SR, Piironen T, Hoyer-Hansen G, Gerstoft J, Pedersen BK, Ullum H: High plasma levels of intact and cleaved soluble urokinase receptor reflect immune activation and are independent predictors of mortality in HIV-1-infected patients. J Acquir Immune Defic Syndr 2005, 39: 23-31. 10.1097/01.qai.0000157950.02076.a6PubMedCrossRef Ostrowski SR, Piironen T, Hoyer-Hansen G, Gerstoft J, Pedersen BK, Ullum H: High plasma levels of intact and cleaved soluble urokinase receptor reflect immune activation and are independent predictors of mortality in HIV-1-infected patients. J Acquir Immune Defic Syndr 2005, 39: 23-31. 10.1097/01.qai.0000157950.02076.a6PubMedCrossRef
16.
go back to reference Pebys MB, Hirschfield GM: C-reactive protein: a critical update. J Clin Invest 2003, 112: 299.CrossRef Pebys MB, Hirschfield GM: C-reactive protein: a critical update. J Clin Invest 2003, 112: 299.CrossRef
17.
go back to reference Wei C, El Hindi S, Li J, Fornoni A, Goes N, Sageshima J, Maiguel D, Karumanchi SA, Yap HK, Saleem M, Zhang Q, Nikolic B, Chaudhuri A, Daftarian P, Salido E, Torres A, Salifu M, Sarwal MM, Schaefer F, Morath C, Schwenger V, Zeier M, Gupta V, Roth D, Rastaldi MP, Burke G, Ruiz P, Reiser J: Circulating urokinase receptor as a cause of focal segmental glomerulosclerosis. Nat Med 2011, 17: 952-960. 10.1038/nm.2411PubMedPubMedCentralCrossRef Wei C, El Hindi S, Li J, Fornoni A, Goes N, Sageshima J, Maiguel D, Karumanchi SA, Yap HK, Saleem M, Zhang Q, Nikolic B, Chaudhuri A, Daftarian P, Salido E, Torres A, Salifu M, Sarwal MM, Schaefer F, Morath C, Schwenger V, Zeier M, Gupta V, Roth D, Rastaldi MP, Burke G, Ruiz P, Reiser J: Circulating urokinase receptor as a cause of focal segmental glomerulosclerosis. Nat Med 2011, 17: 952-960. 10.1038/nm.2411PubMedPubMedCentralCrossRef
18.
go back to reference Berres ML, Schlosser B, Berg T, Trautwein C, Wasmuth HE: Soluble urokinase plasminogen activator receptor is associated with progressive liver fibrosis in hepatitis C infection. J Clin Gastroenterol 2011, 46: 334-338.CrossRef Berres ML, Schlosser B, Berg T, Trautwein C, Wasmuth HE: Soluble urokinase plasminogen activator receptor is associated with progressive liver fibrosis in hepatitis C infection. J Clin Gastroenterol 2011, 46: 334-338.CrossRef
19.
go back to reference Thygesen SK, Christiansen CF, Christensen S, Lash TL, Sørensen HT: The predictive value of ICD-10 diagnostic coding used to assess Charlson comorbidity index conditions in the population-based Danish National Registry of Patients. BMC Res Methodol 2011, 11: 83. 10.1186/1471-2288-11-83CrossRef Thygesen SK, Christiansen CF, Christensen S, Lash TL, Sørensen HT: The predictive value of ICD-10 diagnostic coding used to assess Charlson comorbidity index conditions in the population-based Danish National Registry of Patients. BMC Res Methodol 2011, 11: 83. 10.1186/1471-2288-11-83CrossRef
20.
go back to reference Kofoed K, Eugen-Olsen J, Petersen J, Larsen K, Andersen O: Predicting mortality in patients with systemic inflammatory response syndrome: an evaluation of two prognostic models, two soluble receptors, and a macrophage migration inhibitory factor. Eur J Microbiol Infect Dis 2008, 27: 375-83. 10.1007/s10096-007-0447-5CrossRef Kofoed K, Eugen-Olsen J, Petersen J, Larsen K, Andersen O: Predicting mortality in patients with systemic inflammatory response syndrome: an evaluation of two prognostic models, two soluble receptors, and a macrophage migration inhibitory factor. Eur J Microbiol Infect Dis 2008, 27: 375-83. 10.1007/s10096-007-0447-5CrossRef
Metadata
Title
Plasma suPAR levels are associated with mortality, admission time, and Charlson Comorbidity Index in the acutely admitted medical patient: a prospective observational study
Authors
Thomas Huneck Haupt
Janne Petersen
Gertrude Ellekilde
Henrik Hedegaard Klausen
Christian Wandall Thorball
Jesper Eugen-Olsen
Ove Andersen
Publication date
01-08-2012
Publisher
BioMed Central
Published in
Critical Care / Issue 4/2012
Electronic ISSN: 1364-8535
DOI
https://doi.org/10.1186/cc11434

Other articles of this Issue 4/2012

Critical Care 4/2012 Go to the issue